The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Abstract
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell–specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates complement and antibody-dependent cell-mediated cytotoxicity and has direct antiproliferative effects against malignant B-cell lines in vitro. Phase I trials of single doses up to 500 mg/m2 and 4 weekly doses of 375 mg/m2 showed clinical responses with no dose-limiting toxicity. We conducted a phase II, multicenter study evaluating four weekly infusions of 375 mg/m2 IDEC-C2B8 in patients with relapsed low-grade or follicular NHL (Working Formulation groups A-D). Patients were monitored for adverse events, antibody pharmacokinetics, and clinical response. Thirty-seven patients with a median age of 58 years (range, 29 to 81 years) were treated. All patients had relapsed after chemotherapy (median of 2 prior regimens) and 54% had failed aggressive chemotherapy. Infusional side effects (grade 1-2) consisting of mild fever, chills, respiratory symptoms, and occasionally hypotension were observed mostly with the initial antibody infusion and were rare with subsequent doses. Peripheral blood B-cell depletion occurred rapidly, with recovery beginning 6 months posttreatment. There were no significant changes in mean IgG levels and infections were not increased over what would be expected in this population. Clinical remissions were observed in 17 patients (3 complete remissions and 14 partial remissions), yielding an intent to treat response rate of 46%. The onset of these tumor responses was as soon as 1 month posttreatment and reached a maximum by 4 months posttreatment. In the 17 responders, the median time to progression was 10.2 months (5 patients exceeding 20 months). Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy. One patient developed a detectable but not quantifiable immune response to the antibody that had no clinical significance. IDEC-C2B8 in a dose of 375 mg/m2 weekly for 4 weeks has antitumor activity in patients with relapsed low-grade or follicular NHL. Results with this brief, outpatient treatment compare favorably with results with standard chemotherapy, and IDEC-C2B8 has a better safety profile. Further studies evaluating IDEC-C2B8 in other types of lymphoma either alone or combined with chemotherapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
Self-citationMaloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Self-citationAnderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., & Nadler, L. (1984) · Blood · doi:10.1182/blood.v63.6.1424.1424 · Cited by 704
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Croonian lecture.—On immunity with special reference to cell life
Ehrlich, P. (1900) · Proceedings of the Royal Society of London · doi:10.1098/rspl.1899.0121 · Cited by 441
Press, O. W., Appelbaum, F., Martin, P. J., Matthews, D. C., Bernstein, I. D., Eary, J. F., Nelp, W. B., Gooley, T., Glenn, S., Porter, B., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92225-3 · Cited by 428
A clinical trial of anti-idiotype therapy for B cell malignancy
Meeker, T., Lowder, J., Maloney, D., Miller, R., Thielemans, K., Warnke, R., & Levy, R. (1985) · Blood · doi:10.1182/blood.v65.6.1349.bloodjournal6561349 · Cited by 416
Self-citationIodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Self-citationAmlot, P., Stone, M., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., & Ghetie, V (1993) · Blood · doi:10.1182/blood.v82.9.2624.2624 · Cited by 235
Brown, S., Miller, R., Horning, S., Czerwinski, D., Hart, S., McElderry, R., Basham, T., Warnke, R., Merigan, T., & Levy, R. (1989) · Blood · doi:10.1182/blood.v73.3.651.651 · Cited by 175
Self-citation2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay, A. C., Saven, A., Carrera, C. J., Carson, D. A., Thurston, D., Beutler, E., & Piro, L. D. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.3.371 · Cited by 166
Tedder, T. F., Forsgren, A., Boyd, A., Nadler, L. M., & Schlossman, S. F. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160802 · Cited by 146
Stone, M., Sausville, E., Fay, J. W. J., Headlee, D. J., Collins, R., Figg, W. D., Stetler-Stevenson, M. A., Jain, V. K., Jaffe, E., Solomon, D., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1188.bloodjournal8841188 · Cited by 139
Treatment approaches to the low-grade lymphomas
Horning, S. J. (1994) · Blood · doi:10.1182/blood.v83.4.881.881 · Cited by 103
Maloney, D. G., Brown, S. L., Czerwinski, D. K., Liles, T. M., Hart, S. M., Miller, R., & Levy, R. (1992) · Blood · doi:10.1182/blood.v80.6.1502.1502 · Cited by 78
Self-citation
Cited by
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Metadata
- Authors
- Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., & Levy, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-09-15
- Volume
- 90
- Issue
- 6
- Pages
- 2188-2195
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W206701898
- Cited by
- 1,733
- References
- 21
- FWCI
- 37.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.